The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes of pancreatic intraepithelial neoplasm (PanIN) versus intraductal papillary mucinous neoplasm (IPMN) associated pancreatic adenocarcinoma.
 
Timothy McGinnis
No Relationships to Disclose
 
Leonidas Bantis
No Relationships to Disclose
 
Rashna Madan
No Relationships to Disclose
 
Prasad Dandawate
No Relationships to Disclose
 
Sean Kumer
No Relationships to Disclose
 
Timothy Schmitt
No Relationships to Disclose
 
Ravi Kumar Paluri
Honoraria - Ipsen; Ipsen; Ipsen; Ipsen
Speakers' Bureau - Ipsen; Ipsen; Ipsen; Ipsen
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
 
Anup Kasi
Research Funding - Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); TESARO (Inst); TESARO (Inst); TESARO (Inst); TESARO (Inst)
Travel, Accommodations, Expenses - Halozyme; Halozyme; Halozyme; Halozyme